396 related articles for article (PubMed ID: 22899341)
1. CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges.
Grosse-Gehling P; Fargeas CA; Dittfeld C; Garbe Y; Alison MR; Corbeil D; Kunz-Schughart LA
J Pathol; 2013 Feb; 229(3):355-78. PubMed ID: 22899341
[TBL] [Abstract][Full Text] [Related]
2. Tumour-initiating cells vs. cancer 'stem' cells and CD133: what's in the name?
Neuzil J; Stantic M; Zobalova R; Chladova J; Wang X; Prochazka L; Dong L; Andera L; Ralph SJ
Biochem Biophys Res Commun; 2007 Apr; 355(4):855-9. PubMed ID: 17307142
[TBL] [Abstract][Full Text] [Related]
3. Targeting CD133 antigen in cancer.
Ferrandina G; Petrillo M; Bonanno G; Scambia G
Expert Opin Ther Targets; 2009 Jul; 13(7):823-37. PubMed ID: 19530986
[TBL] [Abstract][Full Text] [Related]
4. The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer.
Horst D; Scheel SK; Liebmann S; Neumann J; Maatz S; Kirchner T; Jung A
J Pathol; 2009 Dec; 219(4):427-34. PubMed ID: 19621338
[TBL] [Abstract][Full Text] [Related]
5. Biology and clinical implications of CD133(+) liver cancer stem cells.
Ma S
Exp Cell Res; 2013 Jan; 319(2):126-32. PubMed ID: 22999864
[TBL] [Abstract][Full Text] [Related]
6. Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data.
Bahnassy AA; Fawzy M; El-Wakil M; Zekri AR; Abdel-Sayed A; Sheta M
Transl Res; 2015 Mar; 165(3):396-406. PubMed ID: 25168019
[TBL] [Abstract][Full Text] [Related]
7. Transcriptional repression of cancer stem cell marker CD133 by tumor suppressor p53.
Park EK; Lee JC; Park JW; Bang SY; Yi SA; Kim BK; Park JH; Kwon SH; You JS; Nam SW; Cho EJ; Han JW
Cell Death Dis; 2015 Nov; 6(11):e1964. PubMed ID: 26539911
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic subpopulations of metastatic colon cancer stem cells: genomic analysis.
Botchkina IL; Rowehl RA; Rivadeneira DE; Karpeh MS; Crawford H; Dufour A; Ju J; Wang Y; Leyfman Y; Botchkina GI
Cancer Genomics Proteomics; 2009; 6(1):19-29. PubMed ID: 19451087
[TBL] [Abstract][Full Text] [Related]
9. High expression of octamer-binding transcription factor 4A, prominin-1 and aldehyde dehydrogenase strongly indicates involvement in the initiation of lung adenocarcinoma resulting in shorter disease-free intervals.
Cortes-Dericks L; Galetta D; Spaggiari L; Schmid RA; Karoubi G
Eur J Cardiothorac Surg; 2012 Jun; 41(6):e173-81. PubMed ID: 22529186
[TBL] [Abstract][Full Text] [Related]
10. Expression of CD133 in synovial sarcoma.
Terry J; Nielsen T
Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):159-65. PubMed ID: 19752721
[TBL] [Abstract][Full Text] [Related]
11. CD133 Expression Is Not Synonymous to Immunoreactivity for AC133 and Fluctuates throughout the Cell Cycle in Glioma Stem-Like Cells.
Barrantes-Freer A; Renovanz M; Eich M; Braukmann A; Sprang B; Spirin P; Pardo LA; Giese A; Kim EL
PLoS One; 2015; 10(6):e0130519. PubMed ID: 26086074
[TBL] [Abstract][Full Text] [Related]
12. CD133 as a marker for regulation and potential for targeted therapies in glioblastoma multiforme.
Choy W; Nagasawa DT; Trang A; Thill K; Spasic M; Yang I
Neurosurg Clin N Am; 2012 Jul; 23(3):391-405. PubMed ID: 22748652
[TBL] [Abstract][Full Text] [Related]
13. CD133: holy of grail of neuro-oncology or promiscuous red-herring?
Donovan LK; Pilkington GJ
Cell Prolif; 2012 Dec; 45(6):527-37. PubMed ID: 23106300
[TBL] [Abstract][Full Text] [Related]
14. Identification of cancer stem cells from human glioblastomas: growth and differentiation capabilities and CD133/prominin-1 expression.
Gambelli F; Sasdelli F; Manini I; Gambarana C; Oliveri G; Miracco C; Sorrentino V
Cell Biol Int; 2012 Jan; 36(1):29-38. PubMed ID: 21916848
[TBL] [Abstract][Full Text] [Related]
15. Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer.
Wang Q; Chen ZG; Du CZ; Wang HW; Yan L; Gu J
Histopathology; 2009 Sep; 55(3):284-93. PubMed ID: 19723143
[TBL] [Abstract][Full Text] [Related]
16. Colon cancer stem cell markers CD44 and CD133 in patients with colorectal cancer and synchronous hepatic metastases.
Jing F; Kim HJ; Kim CH; Kim YJ; Lee JH; Kim HR
Int J Oncol; 2015 Apr; 46(4):1582-8. PubMed ID: 25625240
[TBL] [Abstract][Full Text] [Related]
17. The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells.
Bidlingmaier S; Zhu X; Liu B
J Mol Med (Berl); 2008 Sep; 86(9):1025-32. PubMed ID: 18535813
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of Prominin 1/CD133 expression in colorectal cancer by NSAIDs following short-term preoperative treatment.
Lönnroth C; Andersson M; Nordgren S; Lundholm K
Int J Oncol; 2012 Jul; 41(1):15-23. PubMed ID: 22552364
[TBL] [Abstract][Full Text] [Related]
19. Transcriptome analysis of CD133-positive stem cells and prognostic value of survivin in colorectal cancer.
Kim ST; Sohn I; DO IG; Jang J; Kim SH; Jung IH; Park JO; Park YS; Talasaz A; Lee J; Kim HC
Cancer Genomics Proteomics; 2014; 11(5):259-66. PubMed ID: 25331798
[TBL] [Abstract][Full Text] [Related]
20. The potential role of CD133 in immune surveillance and apoptosis: a mitochondrial connection?
Zobalova R; Prokopova K; Stantic M; Stapelberg M; Dong LF; Ralph SJ; Akporiaye E; Neuzil J
Antioxid Redox Signal; 2011 Dec; 15(12):2989-3002. PubMed ID: 21504364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
